BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24503538)

  • 1. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.
    Turkington RC; Longley DB; Allen WL; Stevenson L; McLaughlin K; Dunne PD; Blayney JK; Salto-Tellez M; Van Schaeybroeck S; Johnston PG
    Cell Death Dis; 2014 Feb; 5(2):e1046. PubMed ID: 24503538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer.
    Ye Y; Jiang D; Li J; Wang M; Han C; Zhang X; Zhao C; Wen J; Kan Q
    Tumour Biol; 2016 Mar; 37(3):3185-95. PubMed ID: 26432329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells.
    Jiang D; Li J; Li J; Wang M; Han C; Wang X; Zhao C; Ye Y
    Int J Oncol; 2017 Nov; 51(5):1611-1620. PubMed ID: 29048661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of the FGFR4 inhibitor PD173074 and 5-fluorouracil reduces proliferation and promotes apoptosis in gastric cancer.
    Ye YW; Hu S; Shi YQ; Zhang XF; Zhou Y; Zhao CL; Wang GJ; Wen JG; Zong H
    Oncol Rep; 2013 Dec; 30(6):2777-84. PubMed ID: 24126887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.
    Ye Y; Li J; Jiang D; Li J; Xiao C; Li Y; Han C; Zhao C
    Cancer Res Treat; 2020 Oct; 52(4):1162-1177. PubMed ID: 32599983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of fibroblast growth factor 4 in the growth and metastasis of colorectal cancer.
    Ye Y; Jiang D; Li J; Han C; Wang X; Wang F; Li J
    Int J Oncol; 2020 Jun; 56(6):1565-1573. PubMed ID: 32236572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
    Allen WL; Stevenson L; Coyle VM; Jithesh PV; Proutski I; Carson G; Gordon MA; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
    Mol Cancer Ther; 2012 Jan; 11(1):119-31. PubMed ID: 22027693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer.
    Li J; Ye Y; Wang M; Lu L; Han C; Zhou Y; Zhang J; Yu Z; Zhang X; Zhao C; Wen J; Kan Q
    Tumour Biol; 2016 May; 37(5):6881-91. PubMed ID: 26662569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer.
    Agarwal S; Afaq F; Bajpai P; Kim HG; Elkholy A; Behring M; Chandrashekar DS; Diffalha SA; Khushman M; Sugandha SP; Varambally S; Manne U
    Mol Oncol; 2022 Apr; 16(8):1728-1745. PubMed ID: 35194944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR4 Links Glucose Metabolism and Chemotherapy Resistance in Breast Cancer.
    Xu M; Chen S; Yang W; Cheng X; Ye Y; Mao J; Wu X; Huang L; Ji J
    Cell Physiol Biochem; 2018; 47(1):151-160. PubMed ID: 29763898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of Fibroblast Growth Factor Receptor 4 by Helicobacter pylori via Signal Transducer and Activator of Transcription 3 With a Feedforward Activation Loop Involving SRC Signaling in Gastric Cancer.
    Zhang X; Soutto M; Chen Z; Bhat N; Zhu S; Eissmann MF; Ernst M; Lu H; Peng D; Xu Z; El-Rifai W
    Gastroenterology; 2022 Sep; 163(3):620-636.e9. PubMed ID: 35588797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
    Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
    EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
    Bai YP; Shang K; Chen H; Ding F; Wang Z; Liang C; Xu Y; Sun MH; Li YY
    Cancer Sci; 2015 Oct; 106(10):1278-87. PubMed ID: 26183471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.
    Stevenson L; Allen WL; Turkington R; Jithesh PV; Proutski I; Stewart G; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
    Clin Cancer Res; 2012 Oct; 18(19):5412-26. PubMed ID: 22859720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.
    Peláez-García A; Barderas R; Torres S; Hernández-Varas P; Teixidó J; Bonilla F; de Herreros AG; Casal JI
    PLoS One; 2013; 8(5):e63695. PubMed ID: 23696849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
    Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
    PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
    Taylor JG; Cheuk AT; Tsang PS; Chung JY; Song YK; Desai K; Yu Y; Chen QR; Shah K; Youngblood V; Fang J; Kim SY; Yeung C; Helman LJ; Mendoza A; Ngo V; Staudt LM; Wei JS; Khanna C; Catchpoole D; Qualman SJ; Hewitt SM; Merlino G; Chanock SJ; Khan J
    J Clin Invest; 2009 Nov; 119(11):3395-407. PubMed ID: 19809159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan.
    Fakhr E; Zare F; Azadmanesh K; Teimoori-Toolabi L
    Biomed Pharmacother; 2021 Nov; 143():112091. PubMed ID: 34474344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.